Mikael Kamras

Mikael Kamras is a veteran Swedish investor and co-founder of Scope Capital Advisory AB. He holds a BSc from the Stockholm School of Economics. Early in his career he ran his own accounting firm, which he sold in 1984–1985 to join the well-known Swedish investment company Proventus AB as Executive Vice President. He rose to become President and CEO of Proventus from 1989 to 2003, and served as Chairman of the Board of Proventus AB in 2002–2004; he has continued to be associated with Proventus as a non-executive director.

In 2001 Kamras co-founded Scope Capital Advisory together with Fredrik Oweson, Andreas Ossmark, Anders Rundgren and (later) Jonas Palmquist. Scope is a Stockholm-based growth/private-equity firm that manages several funds investing in smaller and mid-sized companies, with a particular strength in Nordic consumer brands and technology. Kamras is the firm's Founding Partner and Chairman. Scope's flagship early success was MySQL AB — the first investment of the firm's 2001 fund — which returned roughly 16x invested capital (a profit of more than SEK 300 million) when MySQL was acquired by Sun Microsystems for about USD 1 billion in 2008.

Over a long career Kamras has held numerous board seats across listed and private companies. He has been chairman of listed entities including Orrefors Kosta Boda Holding AB and DNB Kapitalförvaltning AB, and a board member of companies such as Puma AG, Q-Med AB, Monark Stiga AB, Baby-Björn AB, Lamba Electronics, and Programbolaget Nordisk Television AB (TV4). More recently he serves as a board member of Segulah Medical Acceleration (SMA), a Stockholm-based medtech venture firm founded in 2018 that manages roughly SEK 1.3 billion.

Note: while the initial stub described Kamras as an "angel investor / Limited Partner" focused on seed rounds, the strongest public evidence characterizes him primarily as a founding partner and chairman of an established growth/PE firm. He may deploy personal/angel capital, but his documented activity centers on Scope's fund-based investing in growth-stage and consumer/technology companies.

• Invests through Scope Capital Advisory's funds in smaller and mid-sized companies, historically favoring Nordic consumer brands and technology businesses.
• Sector concentration in Scope's portfolio skews toward enterprise applications/software and retail/consumer products.
• Comfortable taking significant/majority stakes and an active ownership role (e.g., Scope acquired roughly half of Happy Socks and led a ~SEK 60M round into Happy Plugs), consistent with a hands-on, board-level value-creation model rather than passive minority checks.
• Backs companies with global scaling potential — the MySQL and RichRelevance outcomes reflect a willingness to support technology businesses that can expand well beyond the Nordics.
• Through Segulah Medical Acceleration, extends into medical technology — medical devices, diagnostics, life-science tools and health tech — at early/growth stage.
• Public statements of a personal, first-person thesis are not readily available; his approach is best inferred from Scope's long track record of brand-building and operational involvement.